The Psoriasis Program, headed up by Dr. Stephanie Mehlis, hosts the Clinical Trials Unit (CTU), which is home to ongoing clinical studies that are investigating the safety and effectiveness of new and currently available drugs for psoriasis, acne and other dermatologic conditions. New studies begin regularly and the CTU continues to recruit patients with psoriasis, acne, atopic dermatitis, rosacea and other dermatologic diseases for ongoing studies.
Our psoriasis therapy study investigated the responses of patients with moderate to severe plaque psoriasis with the goal of determining if a new drug is safe and efficient in treating symptoms. In early trials, patients have achieved a dramatic improvement in their psoriasis with a single dose, with few safety concerns.
The primary objective of our Psoriasis Registry was to study and compare the safety of approved psoriasis therapies used for patients whose psoriasis has been treated by a dermatologist. This included assessing potentially adverse effects and concerns as seen with the real world population of psoriasis patients currently using new biologic therapies. Future studies will test additional drugs used for treating plaque psoriasis to determine their long-term effectiveness, safety and tolerance over a 52 week period.
The clinical trials unit has also extended their research to the benefit of patients with acne. Our researchers are examining the responses to a new form of acne medication in patients suffering from moderate to severe acne over a 12 week period. This study provides important insight into the efficacy and safety of new forms of acne treatment.
Patients interested in participating in clinical trials can contact the Clinical Trials Unit at 847.663.8530 or via email at email@example.com.